

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

COMPLETE IF KNOWN				
Application Number	10/567,470			
Confirmation Number	4986			
Filing Date	November 30, 2006			
First Named Inventor	Iversen et al.			
Group Art Unit	1635			
Examiner Name	Angell, Jon E.			
Attorney Docket No.	50450-8055.US00			

			U.S. P	ATENT DOCUMENTS		
Examiner Initials*	Cite No.	U.S. Patent or App	Kind Code (if known)	Name of Patentee or Inventor of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

3

	FOREIGN PATENT DOCUMENTS						1	
Examin er Initials*	Cite No.	F Office	•	ind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Filing Date of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т
	1.	PCT	WO 02/026968	A1	University of Ottawa	04-04-2002		
	2.	PCT	WO 05/030800	A1	AVI Biopharma, Inc.	04-07-2005		

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т
	3.	AGRAWAL <i>et al.</i> , "Antisense Therapeutics: Is it as Simple as Complementary Base Recognition?", <i>Molecular Medicine Today</i> , <u>6</u> :72-81 (2000).	
	4.	ARORA AND IVERSEN, "Redirection of drug metabolism using antisense technology", Curr. Opin Mol. Ther., 3(3):249-257 (2001).	
	5.	BORIO, L. et al., "Hemorrhagic fever viruses as biological weapons: medical and public health management", <i>The Journal of the American Medical Association</i> , 287(18):2391-2405 (2002).	
	6.	BRAY, M. et al., "A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever", <i>The Journal of Infectious Diseases</i> , 178(3):651-661 (1998).	
	7.	BURNETT, J.C. et al., "The evolving field of biodefence: therapeutic developments and diagnostics", <i>Natural Review Drug Discovery</i> , 4:281-297 (2005).	
	8.	CHIRILLA et al., "The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides", <i>Biomaterials</i> , 23(2):321-342 (2002).	
	9.	Copy of the European Search Report for European application 05796604.6, search report dated, January 5, 2009, 8 pages (2009).	
	10.	CONNOLLY, B.M. et al., "Pathogenesis of experimental Ebola virus infection in guinea pigs", <i>The Journal of Infectious Diseases</i> , <u>179</u> (Suppl. 1):S203-S217 (1999).	

EXAMINER		DATE CONSIDERED
*EXAMINER:		nance with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication t	o application(s).

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

3

2

Sheet

COMPLETE IF KNOWN				
Application Number	10/567,470			
Confirmation Number	4986			
Filing Date	November 30, 2006			
First Named Inventor	Iversen et al.			
Group Art Unit	1635			
Examiner Name	Angell, Jon E.			
Attorney Docket No.	50450-8055.US00			

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т
	11.	COX, N.J. and SUBBARO, K., "Global Epidemiology of Influenza: Past and Present", <i>Annual review Medicine</i> , <u>51</u> :407-421 (2000).	
	12.	COX, N.J. and SUBBARO, K., "Influenza", Lancet, <u>354</u> (9186):1277-1282 (1999).	
	13.	FELDMANN, H. et al., "EBOLA Virus: from Discovery to Vaccine", Nature Review Immunology, 3(8):677-685 (2003).	
	14.	FELDMAN, H. et al., <u>Current Topics in Microbiology and Immunology</u> , Classsification, Structure, and Replication of Filoviruses, pages 1-21 (1999).	
	15.	FELDMAN, H. <i>et al.</i> , "Molecular Biology and Evolution of Filoviruses", <i>Arch. Virol.</i> , <u>7</u> (Suppl.):81-100 (1993).	
	16.	GEISBERT, T.W. and HENSLEY, L.E.,"Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions", <i>Expert Reviews in Molecular Medicine</i> , 6(20):1-24 (2004).	
	17.	GEISBERT, T.W. et al.,"Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys", <i>The Lancet</i> , 362(9400):1953-1958 (2003).	
	18.	GILBERT et al., "Sieve analysis: methods for assessing from vaccine trial data how vaccine efficacy varies with genotypic and phenotypic pathogen variation", <i>Journal of Clinical Epidemiology</i> , 54(1):68-85 (2001).	
	19.	HUDZIAK et al., "Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation", <i>Antisense &amp; Nucleic Acid Drug Developement.</i> , <u>6</u> :267-272 (1996).	
	20.	JAHRLING, P.B. et al., "Evaluation of immune globulin and recombinant interferonal alpha2b for treatment of experimental Ebola virus infections", <i>The Journal of Infectious Diseases</i> , 179(Suppl 1):S224-S234 (1999).	
	21.	MIRANDA, M.B. et al., "Differential activation of apoptosis regulatory pathways during monocytic vs granulocytic differentiation: a requirement for Bcl-X(L)and XIAP in the prolonged survival of monocytic cells", <i>Journal of the Leukemia Society of America</i> , 17(2):1157-79 (2001).	
	22.	PALU et al., "In pursuit of new developments for gene therapy of human diseases", Journal of Biotechnology, <u>68</u> :1-13 (1999).	
	23.	PETERS, C.J. and LEDUE, J.W., "An introduction to Ebola: the virus and the disease", <i>The Journal of Infectious Diseases</i> , <u>179</u> (Suppl 1):ix-xvi (1999).	

EXAMINER		DATE CONSIDERED
		·
*EXAMINER:	Initial if reference considered, whether or not criteria is in conform	nance with MPEP 609. Draw line through citation if not in conformance and not
	considered. Include copy of this form with next communication t	o application(s).

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Form PTO-1449 (Modified) (Use several sheets if necessary)

of

3

Sheet

COMPLETE IF KNOWN			
Application Number	10/567,470		
Confirmation Number	4986		
Filing Date	November 30, 2006		
First Named Inventor	Iversen et al.		
Group Art Unit	1635		
Examiner Name	Angell, Jon E.		
Attorney Docket No.	50450-8055.US00		

		OTHER NON PATENT LITERATURE DOCUMENTS	
Examine r Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published.	Т
	24.	SANCHEZ, A. <i>et al.</i> , "Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus", <i>Virus Research</i> , 29(3):215-240 (1993).	
	25.	SHABBITS, J.A. et al., "Tumor chemosensitization strategies based on apoptosis manipulations", <i>Molecular Cancer Therapeuctics</i> , <u>2</u> (8):805-813 (2003).	
	26.	VLASOV et al., "Inhibition of the Influenza Virus M Protein mRNA Transaltion in vitro with Complementary Oligonucleotides", <i>Nucleosides &amp; Nucleotides</i> , <u>10</u> (1-3):649-650 (1991).	
	27.	WARFIELD, K.I. et al., "Role of natural killer cells in innate protection against lethal ebola virus infection", <i>The Journal of Experimental Medicine</i> , 200(2):169-179 (2004).	
	28.	WILLIAMS, A.S. et al., "A single intra-articular injection of liposomally conjugated methotrexate suppresses joint inflammation in rat antigen-induced arthritis", <i>British Journal of Rheumatology</i> , 35(8):719-724 (1996).	
	29.	ZOLLINGER, W.D. and Moran, E., "Meningococcal vaccinespresent and future", <i>Transactions of Royal Soc of Tropical Medicine and Hygiene</i> , <u>85</u> (Supp. 1):37-43 (1991).	

3

EXAMINER		DATE CONSIDERED
		•
*EXAMINER:	Initial if reference considered, whether or not criteria is in conformation of considered. Include copy of this form with next communication to	mance with MPEP 609. Draw line through citation if not in conformance and not to application(s).